A person holds pharmaceutical tablets and capsules in illustration picture. (Reuters) 
Business

Aurobindo Pharma gets FDA nod to market kidney ailment drug

The approved product has an estimated market size of USD 1.9 billion for the 12 months to May 2017, according to IMS

From our online archive

NEW DELHI: Drug firm Aurobindo Pharma has received final approval from the USFDA to manufacture and market Sevelamer Carbonate tablets in the American market.     

The tablets are indicated for control of serum phosphorus in patients with chronic kidney disease on dialysis.     

"The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture Sevelamer Carbonate tablets 800 mg," Aurobindo Pharma said in a BSE filing today.     

This product, a therapeutic equivalent generic version of Genzyme's Renvela tablets, is being launched immediately.     

The approved product has an estimated market size of USD 1.9 billion for the 12 months to May 2017, according to IMS.     

Aurobindo Pharma has a total of 331 ANDA approvals (294 final nod, including 16 from Aurolife Pharma LLC and 37 tentative approvals) from the US.     

The stock was trading 5.59 per cent higher at Rs 774.75 on the BSE in the morning trade.

Congress leader tasked with drafting 2027 Punjab poll manifesto joins BJP

Odisha evacuates 1.2 lakh people, 69 trains cancelled as Cyclone Akvan approaches with 110 kmph gusts

Elon Musk backs away from Trump's MAGA brand after Republicans' midterm election washout

Rahul Gandhi says India has become ‘side player’ in global affairs as Pakistan negotiates US-Iran peace

Aadhaar card not proof of date of birth: Delhi HC